BR112022016730A2 - Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão - Google Patents

Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão

Info

Publication number
BR112022016730A2
BR112022016730A2 BR112022016730A BR112022016730A BR112022016730A2 BR 112022016730 A2 BR112022016730 A2 BR 112022016730A2 BR 112022016730 A BR112022016730 A BR 112022016730A BR 112022016730 A BR112022016730 A BR 112022016730A BR 112022016730 A2 BR112022016730 A2 BR 112022016730A2
Authority
BR
Brazil
Prior art keywords
alpha
adrenergic receptor
pharmaceutical compositions
improve vision
receptor agonists
Prior art date
Application number
BR112022016730A
Other languages
English (en)
Portuguese (pt)
Inventor
Graham Richard
Wu Ke
Fahid Massoud
Dibas Mohammed
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112022016730A2 publication Critical patent/BR112022016730A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112022016730A 2020-02-20 2021-02-19 Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão BR112022016730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979214P 2020-02-20 2020-02-20
PCT/US2021/018906 WO2021168349A1 (en) 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Publications (1)

Publication Number Publication Date
BR112022016730A2 true BR112022016730A2 (pt) 2022-11-08

Family

ID=74875311

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016730A BR112022016730A2 (pt) 2020-02-20 2021-02-19 Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão

Country Status (12)

Country Link
US (2) US20210260041A1 (https=)
EP (1) EP4106728A1 (https=)
JP (1) JP2023514732A (https=)
KR (1) KR20220157392A (https=)
CN (1) CN115443125A (https=)
AU (1) AU2021224232A1 (https=)
BR (1) BR112022016730A2 (https=)
CA (1) CA3168767A1 (https=)
IL (1) IL295782A (https=)
MX (1) MX2022010317A (https=)
TW (1) TW202139998A (https=)
WO (1) WO2021168349A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途

Also Published As

Publication number Publication date
EP4106728A1 (en) 2022-12-28
MX2022010317A (es) 2023-01-24
AU2021224232A1 (en) 2022-10-13
CA3168767A1 (en) 2021-08-26
US20210260041A1 (en) 2021-08-26
TW202139998A (zh) 2021-11-01
JP2023514732A (ja) 2023-04-07
KR20220157392A (ko) 2022-11-29
US20240335425A1 (en) 2024-10-10
CN115443125A (zh) 2022-12-06
WO2021168349A1 (en) 2021-08-26
IL295782A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CL2017002526A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015)
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
EA202092225A1 (ru) Соединения и их применение
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
CL2021000440A1 (es) El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión.
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
MX2021014357A (es) Metodos y formulaciones para tratar trastornos de la vision.
BR112022016730A2 (pt) Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão
BR112012015386B8 (pt) composição oftálmica tópica
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
BR112013005224A2 (pt) "agonistas de adenosina a1 para o tratamento de glaucoma e hipertensão ocular".
MX375963B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
MX420447B (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements